medigraphic.com
ISSN 0188-2198 (Impreso)

2015, Número 2

<< Anterior Siguiente >>

Rev Mex Cardiol 2015; 26 (2)


Regresión del grosor de la interfase íntima-media carotídea con nifedipina en pacientes hipertensos (REINA)

Meaney A, Solache G, Reyes MVM, Gutiérrez-Salmeán G, Ceballos G, Meaney E

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 87-94
Archivo PDF: 231.44 Kb.


RESUMEN

Antecedentes: Los bloqueadores de los canales de calcio (BCC) han demostrado reducir tanto los niveles de presión arterial como los eventos cardiovasculares, incluyendo el desarrollo de la aterosclerosis. El estudio INSIGHT mostró una progresión menos pronunciada del grosor de la capa íntima-media de la carotídea (GIMC) en pacientes tratados con nifedipina (NIF) vs. los tratados con diuréticos, pero debido a que el GIMC fue normal en ambos grupos, resultó difícil evaluar el efecto anti-aterosclerótico de la NIF. El presente estudio comparó el efecto de la NIF o hidroclorotiazida (HCTZ) en la regresión de aterosclerosis en pacientes hipertensos con GIMC anormalmente gruesa. Pacientes y métodos: 37 pacientes hipertensos fueron asignados al azar para ser tratados con NIF de liberación lenta (30 mg) y 46 a HCTZ (25 mg), todos ellos con GIMC › 0.6 mm. GIMC, perfil lipídico, y ácido úrico en suero, potasio y glucosa se analizaron al principio y 12 meses más tarde. Discusión: Los BCC restauran la función endotelial, ejercen actividad antioxidante y limitan el crecimiento y la proliferación de las células del músculo liso, inhibiendo así fenómenos aterogénicos fundamentales. Nuestros resultados muestran una clara regresión del GIMC, marcador de aterosclerosis subclínica, con NIF. Conclusión: Ambos tratamientos fueron igualmente efectivos para reducir la presión arterial. HCTZ no causó desorden metabólico, pero sólo la NIF induce la regresión del GIMC. El GIMC basal es un determinante principal de la regresión.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chobanian AV. Vascular effects of systemic hypertension. Am J Cardiol. 1992; 69: 3E-7E.

  2. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens. 2005; 14: 125-131.

  3. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension. 1992; 20: 253-263.

  4. Erusalimsky JD, Kurz DJ. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontol. 2005; 40: 634-642.

  5. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011; 123: 327-334.

  6. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction. The Rotterdam study. Circulation. 1997; 96: 1432-1437.

  7. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000; 356: 1955-1964.

  8. Trenkwalder P. Antihypertensive treatment with calcium channel blockers: pharmacological pornography or useful intervention? Nephrol Dial Transplant. 2004; 19: 17-20.

  9. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C et al. Health outcomes associated with calcium channel antagonists compared with other first-line antihypertensive therapies: a metaanalysis of randomised controlled trials. Lancet. 2000; 356: 1949-1954.

  10. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckber SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and metaanalysis. JAMA. 1997; 277: 739-745.

  11. Simon A, Levenson J. Effects of calcium channel blockers on atherosclerosis: new insights. Acta Cardiol. 2002; 57: 249-255.

  12. Tzivoni D. End organ protection by calcium-channel blockers. Clin Cardiol. 2001; 24: 102-106.

  13. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356: 366-372.

  14. Gariepy J, Simon A, Chironi G, Moyse D, Levenson J. Large artery wall thickening and its determinants under antihypertensive treatment: the IMT-INSIGHT study. J Hypertens. 2004; 22: 137-143.

  15. World Medical Association, Declaration of Helsinki. Adopted in the 18th World Medical Assembly. Helsinki (Finland, 1964) and corrected in the 29th Assembly (Tokyo, Japan 1975), the 35th (Venice, Italy, 1983) and the 41 (Hong Kong, 1989). Available in: http://ohsr. od.nih.gov/helsinki.php3.

  16. ICH Guidelines for Good Clinical Practice. International Conference on Harmonisation for Technical Requirements for the Registration of Pharmaceuticals for Human Use. ICH Harmonised tripartite R Guideline. London. ICH. 1996.

  17. Ley General de Salud, Reglamento de Investigación Clínica. Título 5o. Capítulo único. Diario Oficial de la Federación, el 24 de diciembre de 1986.

  18. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013; 31: 1281-1357.

  19. Friedwald WT, Levy IR, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.

  20. Sidhu PS, Desai SR. A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Br J Radiol. 1997; 70: 85-89.

  21. Lim TK, Lim E, Dwivedi G, Kooner J, Senior R. Normal value of carotid intima-media thickness-a surrogate marker of atherosclersosis: quantitative assessment by B-mode carotid ultrasound. JASE. 2008; 21: 112-116.

  22. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002; 20: 159-169.

  23. Jarauta E, Mateo-Gallego R, Bea A, Burillo E, Calmarza P, Civeira F. Carotid intima-media thickness in subjects with no cardiovascular risk factors. Rev Esp Cardiol. 2010; 63: 97-102.

  24. Dahlöf B. End-organ damage: does it really matter how we prevent it? Eur Heart J. 2003; 5 (Suppl F): F33-F39.

  25. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract. 2008; 62: 1246-1254.

  26. Espeland MA, Craven TE, Riley WA, Corson J, Romont A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses for the Asymptomatic Carotid Artery Progression Study Research Group. Stroke. 1996; 27: 480-485.

  27. Hulthe J, Wikstrand J, Emanuelsson H, Wiklund O, de Feyter PJ, Wendelhag I. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke. 1997; 28: 1189-1194.

  28. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke. 2000; 31: 2426-2430.

  29. Agewall S, Fagerberg B, Berglund G, Schmidt C, Wendelhag I, Wikstrand J et al. Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. J Intern Med. 2001; 249: 305-314.

  30. Cuspidi C, Negri F, Giudici V, Capra A, Sala C. Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials. Integr Blood Press Control. 2009; 2: 1-8.

  31. Terpstra WF, May JF, Smit AJ, de Graeff PA, Crijns HJ. Effects of nifedipine on carotid and femoral arterial wall thickness in previously untreated hypertensive patients. Blood Press Suppl. 2003; 1: 22-29.

  32. Tropeano AI, Saleh N, Hawajri N, Macquin-Mavier I, Maison P. Do all antihypertensive drugs improve carotid intima-media thickness? A network metaanalysis of randomized controlled trials. Fundam Clin Pharmacol. 2011; 25 (3): 395-404.

  33. Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358: 1431-1443.

  34. Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem. 2008; 54: 940-942.

  35. Orio F Jr, Palomba S, Cascella T, De Simona B, Manguso F, Savastano S et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrin Metab. 2005; 90: 6072-6076.

  36. Mason RP. Pleiotropic effects of calcium channel blockers. Curr Hypertens Rep. 2012; 14: 293-303.

  37. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists. Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003; 23: 2155-2163.




2020     |     www.medigraphic.com